nicht-klinischen/präklinischen Studien für den Menschen wird derzeit untersucht. Für weitere Informationen kontaktieren Sie bitte: Dr. Peer Nils Schröder Head of Corporate Communications & Investor Relations Telefon +41 61 606 1102 E-Mail media_relations@basilea.com investor_relations@basilea.com Diese Pressemitteilung ist unter www.basilea.com abrufbar. Quellenangaben Hinweis: Aus Gründen der Lesbarkeit wurde in der Pressemitteilung die männliche Form ,,Patienten" gewählt, jedoch beziehen sich die Angaben auf Angehörige aller Geschlechter. 1. FIDES-01: ClinicalTrials.gov-Identifier: NCT03230318 2. Topline-Ergebnisse für die Kohorte 1 der FIDES-01-Studie wurden am 10. Februar 2021 veröffentlicht (siehe Pressemitteilung https://www.basilea.com/news/news/basilea-gibt-positive-topline-ergebnisse-aus-phase-2-studie-fides-01-mit-derazantinib-bei-patienten-mit-gallengangkrebs-icca-und-fusionen-des-fgfr2-gens-bekannt ) 3. T. G. Hall, Y. Yu, S. Eathiraj et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS ONE 2016, 11 (9), e0162594 4. R. Porta, R. Borea, A. Coelho et al. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Critical Reviews in Oncology/Hematology 2017 (113), 256-267 5. T. Helsten, S. Elkin, E. Arthur et al. The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer Research 2016 (22), 259-267 6. P. McSheehy, F. Bachmann, N. Forster-Gross et al. Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer. Molecular Cancer Therapeutics 2019 (18), 12 Supplement, pp. LB-C12 7. M. A. Cannarile, M. Weisser, W. Jacob et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy of Cancer 2017, 5:53 8. Y. Zhu, B. L. Knolhoff, M. A. Meyer et al. CSF1/CSF1R Blockade reprograms tumor-infiltrating macrophages and improves response to T cell checkpoint immunotherapy in pancreatic cancer models. Cancer Research 2014 (74), 5057-5069 9. E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti--PD-1 treatment. Proceedings of the National Academy of Science of the United States of America 2018 (115), E4041-E4050 10. V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120), 165-171. ClinicalTrials.gov-Identifier: NCT01752920 11. FIDES-02: ClinicalTrials.gov-Identifier: NCT04045613 12. FIDES-03: ClinicalTrials.gov-Identifier: NCT04604132 13. S. K. Saha, A. X. Zhu, C. S. Fuchs et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. The Oncologist 2016 (21), 594-599 14. A. Lamarca, D. H. Palmer, H. S. Wasa et al. ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. Journal of Clinical Oncology 2019 (37), Supplement, Abstract 4003 Anhang -- Pressemitteilung (PDF) https://ml-eu.globenewswire.com/Resource/Download/5476f411-05ef-4f28-ade4-24052d0e7c86
(END) Dow Jones Newswires
March 24, 2021 02:15 ET (06:15 GMT)